IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
An Overview on HPV in Head and Neck Squamous Cell Carcinoma

Author: MS. LAEEQ, DR.SHALINI GUPTA, DR.MOHATSIM LOHANI
Abstract: Head and Neck Squamous Cell Carcinoma malignant disease is associated with human papillomavirus (HPV) 16 infection. Human papillomavirus (HPV) is a virus often infecting humans. It is often present on skin or mucous membranes. This diverse DNA virus is often linked to many various benign and malignant neoplastic lesions. The biology of HPV-positive oropharyngeal cancer is distinct with P53 degradation, retinoblastoma RB pathway inactivation, and P16 upregulation. By contrast, tobacco-related oropharyngeal cancer is characterised by TP53 mutation and downregulation of CDKN2A (encoding P16). The best method to detect virus in tumour is controversial, and both in-situ hybridisation and PCR are commonly used; P16 immunohistochemistry could serve as a potential surrogate marker. HPV-positive oropharyngeal cancer seems to be more responsive to chemotherapy and radiation than HPV-negative disease. Many patients with oropharyngeal cancer have no common risk factors, and recent epidemiologic and molecular studies have identified high-risk types of human papillomavirus (HPV), especially HPV- 16, as the potential etiologic agents. The widespread use of prophylactic HPV vaccines combined with vigilant Pap smear and HPV-DNA testing has the potential to eliminate many of these cancers. In the future, antiviral pharmaceutical approaches and therapeutic vaccination may allow effective, nontoxic therapy.
Keyword: HPV, OSCC, Vaccines, Targeted therapies, Immunotherapy,Tumour.
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free